Compare Las Vegas Sands Corp. (LVS) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Las Vegas Sands Corp. vs ResMed Inc. — how do they compare? Las Vegas Sands Corp. trades at $45.5 (market cap $30.36B), while ResMed Inc. trades at $197.45 (market cap $28.81B). The key difference: Las Vegas Sands Corp. and ResMed Inc. are close in size by market cap, and Las Vegas Sands Corp. pays the higher dividend (2.4%). Which is the better fit depends on your goals.
| LVS | RMD | |
|---|---|---|
Market Cap | $30.36B | $28.81B |
Sector | Consumer Cyclical | Health |
52-Week High | $69.49 | $293.73 |
52-Week Low | $44.78 | $182.82 |
Enterprise Value | $42.75B | $27.99B |
Dividend Yield | 2.4% | 1.21% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
